You are here: Industry Insights > antibodies

News List

Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing WND/PharmaSources
December 14, 2023
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
What are the benefits of COVID-19 vaccine? PharmaSources/Big Cat of Medical Field
June 17, 2021
When it comes to the benefits of vaccines, the first thing we are going to talk about is the stem of the vaccines - influenza virus.
Calypso Enters into Agreement to Be Acquired by Novartis B3C newswire
January 08, 2024
Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmuneindications
Maxion Therapeutics Awarded £2 Million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-To-Treat" Autoimmune Diseases PharmaSources
April 20, 2023
Maxion therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “Hard-To-Treat" autoimmune diseases.
serYmun Yeast Announces Preclinical Safety and Efficacy Data for Their Yeast-Based Vaccine Against Porcine Parvovirus (PPV) PharmaSources
March 06, 2023
an animal health vaccine development company based in Germany, announces the breakthrough in the development of their first pig vaccine candidate against porcine parvovirus.
COVID Infection May Boost Antibodies for Up to 20 Months drugs.com
February 07, 2022
If you've already had COVID-19, your natural antibodies may last as long as 20 months, a new study suggests.
Anti-RBD Antibodies Detected Up to 20 Months After COVID-19 drugs.com
February 07, 2022
Anti-receptor binding domain (RBD) antibodies are detected in 99 percent of unvaccinated individuals...
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital prnasia
January 29, 2022
HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed a US$40 million Series...
MU study identifies mutations specific to Omicron variant FirstWordPharma
January 24, 2022
While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant's high rate of infection.
Fourth COVID vaccine partially effective against Omicron: Israeli study ExpressPharma
January 20, 2022
A fourth dose of COVID-19 vaccine boosts antibodies to higher levels than the third jab but provides only partial protection against the Omicron variant of coronavirus, according to a preliminary study conducted in Israel.

Previous page 1 2 3 4 5 6 Next page